Alaric has been covering the biopharma industry and health care for more than 14 years. His areas of focus include clinical trials, drug development in hematology-oncology, cell and gene therapy and the industry's growing use of artificial intelligence and machine learning. He holds a bachelor's degree in journalism from Ball State University and previously lived in China for three years.

Latest from Alaric DeArment

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions

Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.

Rocket Comes Back To Earth With Restructuring Plan

The biotech will lay off nearly one-third of its workforce and focus on its cardiovascular gene therapy programs.

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.

AstraZeneca Pledges Big Investment In US Manufacturing Amid Tariff Threats

The drugmaker plans to build a large manufacturing center in Virginia as the centerpiece of an effort to invest $50bn in the US by 2030.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.